Corporate Banner
Satellite Banner
Technology Networks Header
Sunday, November 23, 2014
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Molecular Event Mapping Opens Door to more in silico Tests
It is hoped that this new approach to mapping and predicting the impact of chemical compounds in the body could reduce the need for toxicity tests in animals.
Protein-engineered Cages Aid Studies of Cell Functions
The Cages, from researchers at Tokyo Institute of Technology, to deliver an important signalling molecule, carbon monoxide, into cells.
Wallet-Sized Labs The Next Big Thing
RMIT researchers are developing inexpensive, portable toxicology laboratories so small you could fit them in your wallet.
Altered Milk Protein Can Deliver AIDS Drug to Infants
Binding with an antiretroviral drug promises to greatly improve treatment for infants and young children suffering from HIV/AIDS.
New Drug for Common Liver Disease Improves Liver Health
An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the NIH.
Immunotherapy for Cancer Toxic with Obesity
UC Davis researchers link increased body fat and lethal drug reactions in mice.
An Unlikely Use for Diamonds
Tiny diamonds provide new possibilities for accurate measurements of processes inside living cells with potential to improve drug delivery and cancer therapeutics.
Microscopic “Walkers” Find Their Way Across Cell Surfaces
Technology could provide a way to deliver probes or drugs to cell structures without outside guidance.
Revalesio’s Drug Shows Promise in Treating Alzheimer’s
Multiple published research studies outline the potential for RNS60 to effectively treat Alzheimer’s disease by protecting neuronal function and restoring neuronal plasticity.
Getting Metabolism Right
Analysis of 89 models of metabolic processes finds flaws in 44 of them — but suggests corrections.
Scroll Up
Scroll Down
Return
Drug-Drug Interactions Involving non-CYP Phase I or Phase II Enzymes can we Predict?
Olivier Barberan, Director of Product Development, Aureus Pharma, speaking at ADMET Europe
Date Posted: Thursday, September 16, 2010
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Aureus Pharma Announces Participation in EUR 118 Million Biointelligence R&D Programme
The programme is aimed to promote the use of Systemic Modelling and Simulation Tools In The Life Science Industry.
Tuesday, March 23, 2010
Aureus Pharma Extends its Knowledge Database Agreement with Sanofi-Aventis R&D
Aureus will provide new AurSCOPE® knowledge databases and continue to update existing databases for sanofi-aventis' R&D division.
Friday, November 06, 2009
Aureus Pharma to Participate in a European Consortium for Drug Cardiac Toxicity
Aureus’ contribution to the project will be to use its expertise in Ion Channel/hERG knowledge databases to predict the effects of drugs on the heart.
Friday, October 31, 2008
Aureus Pharma Licenses AurWEB to Origenis
AurWEB is designed to allow access to all of Aureus’ knowledge databases, which include AurSCOPE GPCR, Ion Channel, Kinase, ADME/Drug-Drug interactions and hERG.
Thursday, September 07, 2006
Aureus Licenses AurSCOPE ADME/DDI and hERG Knowledge Databases to Siena
Aureus’ ADME/DDI and hERG knowledge databases contain data which can help assess the safety of a potential pharmaceutical candidate.
Thursday, June 08, 2006
 
SELECTBIO
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv